Jinan High-tech Development Co (600807) Fair Value & Analysis
Real Estate · CN · Market cap 2.3B CNY
Fair value as of: Jun 26, 2026
Analysis
Jinan High-tech Development Co (600807) currently trades at ¥2.38, while our model-based Fair Value estimate is ¥0.5000 — implying the stock looks roughly 79.0% overvalued today. We read business quality at 80/100 (high quality), in the Real Estate sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Jinan High-tech Development Co., Ltd., together with its subsidiaries, engages in the in-vitro diagnostics, trading, real estate, and property service businesses in China. It offers molecular diagnostic automated testing equipment, including automatic nucleic acid detection system, nucleic acid workstation, and nucleic acid extraction and purification instrument, as well as fluorescence quantitative PCR instrument, etc.; medical and health services; and technology and engineering consulting services in the field of biosafety. The company also provides real estate development services; and property services, including cleaning, security, greening maintenance, equipment and facility management, and payment of water and electricity bills, as well as trades in steel bars. Jinan High-tech Development Co., Ltd. was founded in 1993 and is based in Jinan, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Jinan High-tech Development Co (600807) undervalued?
What is the fair value of 600807?
What is the quality score of 600807?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.